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ABSTRACT 
Background: A series of studies has suggested some efficacy of gluco- 
samine in arthrosis of the knee, but virtually no documentation exists regarding 
its effects on low back pain. 
Objectives: The primary objective of this study was to examine whether a 
12-week course of a glucosamine complex (GC) could benefit patients having 
low back pain despite a course of noninvasive physical therapy. In addition, we 
sought to delineate the subgroup of responders. 
Methods: This open-label, randomized, controlled study was conducted 
at the Division of Rheumatology and Physical Medicine, Erasme University 
Hospital, Brussels, Belgium. Male and female outpatients aged 40 to 80 years 
with low back pain (duration, ___12 weeks; pain score on 10-cm visual analog 
scale [VAS] [0 = none to 10 = worst imaginable], ---3 cm) despite noninvasive 
physical therapy (massage, stretching, heat application, and analgesics for 
>4 weeks) were included. Patients were randomly assigned to receive, in ad- 
dition to conventional treatment (CT) (physical therapy plus analgesics/anti- 
inflammatories), a GC (enriched with sulfonyl methane, silicon, and a botanical 
extract of Ribes nigrum) or CT alone (control) for 12 weeks. Pain at rest and on 
movement (effort) and early morning lumbar stiffness were measured every 
4 weeks using the VAS. The primary end point was improvement in VAS score 
for pain at rest at 12 weeks. Two validated questionnaires were used to assess 
improvements in quality of life (QOL) (Oswestry Disability Questionnaire [ODQ] 
[10 items; scale: 0 = no disability to 60 = maximal disability] and Roland-Morris 
Disability Questionnaire [RMDQ] [24 items; scale: 0 = no disability to 24 = 
severe disability]). Responders were defined as patients who positively assessed 
the efficacy of the GC. At each visit, patients were also asked about possible 
adverse vents. 
Results: Of 36 enrolled patients, 32 completed the study (18 men, 14 women; 
mean [SE] age, 64 [2] years; 17 in the GC group and 15 in the control group). 
Four patients were lost to follow-up. At week 4, changes from baseline VAS scores 
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for pain at rest and lumbar stiffness were significantly greater in the GC group 
compared with the control group (P < 0.001 and P = 0.011, respectively). At week 4, 
QOL was found to be improved, as measured using the ODQ, in the GC group 
compared with the control group (P = 0.028), but the between-group difference as 
measured using the RMDQ was not significant. The improvements from baseline 
on the questionnaires were sustained over the 12-week period in the GC group 
(all, P < 0.001). Gastrointestinal dverse effects were reported by 1 GC-treated 
patient and 1 patient in the control group, but neither patient withdrew from the 
study. Of the 17 GC-treated patients, 9considered themselves responders, but the 
profile of a responder could not be delineated. 
Conclusions: In this study in patients with low back pain, analgesic effect 
and improvement in QOL were found with the use of GC. GC was well tolerated. 
(Curt Ther Res Clm Exp. 2005;66:511-521) Copyright © 2005 Excerpta Medica, Inc. 
Key words: arthrosis, back pain, glucosamine, methylsulfonylmethane, sili- 
con, Ribes nigrum. 
INTRODUCTION 
A series of studies upport he efficacy of glucosamine in patients with arthro- 
sis of the knee, with efficacy being defined as decreased pain and morning lum- 
bar stiffness, increased quality of life (QOL), and ability to walk. 1'2 A meta- 
analysis of randomized, controlled trials in patients with knee arthrosis found 
that glucosamine might be well tolerated and effective in delaying the progres- 
sion of arthrosis and improving symptoms. 3 Based on the results from Poolsup 
et al, 4 the administration of glucosamine for several years has been associat- 
ed with increased cartilage thickness. The mode of action of glucosamine is
attributed to a direct effect on the chondrocytes and to an anti-inflammatory 
effect. 2
Low back pain is a ubiquitous health problem; between 65% and 80% of people 
worldwide are affected at some point during their lives. Physical therapies, pa- 
tient education, and drug therapy are the cornerstones of treatment. However, 
this approach is not sufficiently effective in many patients, especially if the 
condition is chronic (>12 weeks). 5
NSAIDs are effective for short-term symptomatic relief in acute episodes of 
low back pain. However, sufficient evidence for their effects on chronic low 
back pain is lacking, 6and to date, there is no consensus or specific guidelines 
for the management of chronic low back pain. 7 For these reasons, many patients 
with chronic backache (and other chronic rheumatic onditions) look for oth- 
er treatments. Accordingly, about half of rheumatology patients use comple- 
mentary and/or alternative medicine, including nutraceuticals and phyto-anti- 
inflammatory drugs. 8A substantial evidence base is beginning to emerge for 
the efficacy of a few nutraceuticals and medicinal plants in the treatment of 
musculoskeletal disease, notably glucosamine, adenosyl methionine, silicon, 
and Ribes nigrum (black currant), with data suggestive of potential chondropro- 
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tective, anti-inflammatory, anti-metalloproteasic, anti-cyclooxygenase-2, and bone- 
protective activities. 8-16 
In this study, we used a commercially available glucosamine complex (GC) 
containing lucosamine sulfate 750 mg, enriched with 100 mg of a botanical 
extract of Ribes nigrum, containing flavonoids, phenols, and prodelphinidins, 
with anti-inflammatory properties. It was also enriched with methylsulfonyl- 
methane 1000 mg (a sulfur found in fruits and vegetables and thought o pos- 
sess analgesic effects in degenerative rheumatisms 12)and colloidal silicon 50 mg 
(associated with increased trabecular bone volume9-13,16). For osteoarthritis, 
the recommended dosage of this GC is 2 powder sachets per day for at least 
12 weeks. 17 
The majority of the studies showing clinical benefit of glucosamine have 
focused on arthrosis of the knee, hip, or thumb, 2 but based on a literature 
search using MEDLINE (key terms: glucosamine and low back pain; years: 
1965-2005), no studies in patients with painful common lumbar arthrosis have 
been published, even though all of these disorders are of degenerative origin, 
are linked to the mechanical nature of the pain, and share a similar therapeutic 
approach. 1-3 
Therefore, the aim of this study was to determine whether the addition of GC 
BID for 12 weeks to a regimen of conventional treatment (CT) would clinically 
benefit patients with common chronic low back pain and arthrosis. 
PATIENTS AND METHODS 
This randomized, open-label, controlled pilot study was conducted at the Divi- 
sion of Rheumatology and Physical Medicine, Erasme University Hospital, Brussels, 
Belgium. 
Inclusion and Exclusion Criteria 
Male and female patients between 40 and 80 years of age were recruited 
from a group of consecutive outpatients referred between January and April 
2004 for the treatment of chronic low back pain with associated signs of lum- 
bar arthrosis on radiography (eg, uni- or multilevel intervertebral disc space 
narrowing, condensation of the vertebral plateaus, osteophytosis, degenera- 
tive changes of the interapophyseal joint). To be eligible for the study, patients 
had to have been receiving stable treatment with analgesic/anti-inflammatory 
drugs and standard physical rehabilitation, including massage, stretching, and 
heat application, twice weekly for at least 4 weeks, without sufficient clinical 
improvement (pain score ---3 on a 10-cm visual analog scale [VAS] [0 = no pain 
to 10 = worst possible pain]). All patients were undergoing monthly consulta- 
tions at the clinic. 
Patients were excluded if they had any known cause of low back pain other 
than lumbar arthrosis (eg, osteoporosis, spondyloarthropathy, metastasis, Paget's 
disease) or any factor that could interfere with the efficacy assessment (eg, de- 
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pression, anxiety, fibromyalgia, gastrointestinal disturbance). This information 
was obtained from patients' medical files and during the inclusion visit. 
This pilot study used questionnaires concerning a neutraceutical (not regis- 
tered as a drug but as a food supplement), and was performed before the 2004 
publication of the new Legislation on Experimentation concerning experiments on 
humans (following the European Directive). Thus, the protocol was not submitted 
to an ethics committee for approval. Nonetheless, prior to inclusion, patients were 
informed of the aim of the study, the characteristics of the GC, and the benefits and 
risks expected from the administration of the GC and from continuing with their 
CT regimen; each patient's oral informed consent was obtained. 
Treatment 
Patients' CT regimens (anti-inflammatory and physical therapy) were to re- 
main stable throughout the study period. Patients were selected randomly by 
means of a randomization table by Pocock 16 to receive GC (2 powder sachets 
per day [with meals]) or CT alone (control group) for 12 weeks. Patients agreed 
to be reevaluated during their monthly consultations. Neither the investigators 
nor the patients were blinded to treatment assignment. 
Efficacy Assessments 
To assess the level of clinical benefit, we used clinical parameters (VAS 
scores for pain and lumbar stiffness and 2 QOL questionnaires). 
Intensity of Lumbar Pain and Stiffness 
Patients were asked to rate their pain at rest, pain on movement, and lumbar 
stiffness in the past 24 hours on the VAS. 
Quality of Life 
To assess QOL, measured as function in performing activities of daily living, 
patients were asked to complete (in the absence of the physician) the validated 
Oswestry Disability Questionnaire (ODQ) 16'18-20 and Roland-Morris Disability 
Questionnaire (RMDQ). 18,19 The 10-item ODQ 16,18,19 takes into account and quan- 
tifies incapability of movement while the patient washes and dresses, carries 
weights, walks, and sits or stands up; quality of sleep and social life; traveling 
comfort; and the evolution of the pain (scale: 0 = no disability to 60 = maximal 
disability). The RMDQ 18,19 is another QOL questionnaire with 24 items that does 
not note the severity of each item but mainly focuses on yes  or no responses 
about positions and situations causing lumbalgia (eg, when remaining seated, 
walking, getting up, bending over, getting dressed) (scale: 0 = no disability to 
24 = severe disability). 
Patient Global Assessment 
At the end of the study, patients were asked to provide a global assessment of
the treatment they received (ie, "Were you satisfied?"; possible answers: yes [pos- 
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itive] or no [negative]), 18,21 and whether they believed they could discontinue 
their regular consumption of analgesic/anti-inflammatory drugs. Responders were 
defined as patients who positively assessed the efficacy of the GC. 
Tolerability and Compliance Assessments 
At each clinic visit, patients were interviewed concerning any undesirable 
effects (especially pyrosis, nausea, abdominal cramps, diarrhea, rash, fatigue, 
malaise, and any other adverse event), and about their compliance with the 
treatment regimen. 
Statistical Analysis 
A per-protocol analysis (without prior power analysis for determining sam- 
ple size) was used. 22 The normality of the variable distribution was verified 
using the Shapiro-Wilks test. The statistical analysis consisted of an analysis of 
variance (ANOVA) of 2 factors (groups and periods of time) with frequent mea- 
suring of the periods of time and the interaction time with the group. Although 
the F ratio on ANOVA was found to be significant, we compared the means using 
a modified t test for paired data. Baseline demographic and clinical characteris- 
tics were compared between the 2 treatment groups and the 2 subgroups 
(responders vs nonresponders)  using the Student test for independent mea- 
sures. The threshold P < 0.05 was considered statistically significant. The results 
are expressed as mean (SE). 22 SPSS version 2 (SPSS Inc., Chicago, Illinois) was 
used in the calculations. 
RESULTS 
Patient Population 
Thirty-six patients were enrolled in the study. Four patients (1 in the glu- 
cosamine group and 3 in the control group) were lost to follow-up and were not 
included in the intent-to-treat nalysis; the remaining 32 patients completed the 
study and were included in the safety analysis (18 men, 14 women; mean [SE] 
age, 64 [2] years; GC group, 17 patients; control  group, 15 patients). No sig- 
nificant differences in male/female ratio, age, duration of low back pain, or con- 
comitant use of anti - inf lammatory/analgesic drugs were found between the 
2 groups (Table I). 
Efficacy 
Pain at  Rest 
In the GC group, the VAS score was significantly improved from baseline at 
4, 8, and 12 weeks (all, P < 0.001). At 4 weeks of treatment, the mean change 
from baseline in VAS score for pain at rest was significantly greater in the group 
of patients treated with the GC compared with that in the control group (-2.18 vs 
+0.13; P < 0.001). This difference continued at weeks 8 and 12 (both, P < 0.01) 
(mean VAS changes at 12 weeks, -4.06 in the GC group vs -1.46 in the control 
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Table I. Demographic and baseline clinical characteristics of the study patients.* 
GC Control 
Characteristic (n = 1 7) (n = 15) 
Age, mean (SE), y 67 (3) 62 (4) 
Sex, no. 
Male 10 8 
Female 7 7 
Duration of back pain, mean (SE), y 9.8 (2.4) 7.8 (2.0) 
GC = glucosamine complex. 
*No significant between-group differences were found. 
group). Throughout  he 12-week t reatment  period, the mean VAS score for 
pain at rest was statistically similar to that at baseline in the control group 
(Table II). 
Pain on Movement  
The mean (SE) VAS score for pain on movement in the GC group was signifi- 
cantly lower at 4 weeks compared with baseline (3.60 [0.73] vs 6.17 [0.38]; P< 
0.001); the differences at weeks 8 and 12 were nonsignificant. In the control 
group, the mean (SE) VAS score was significantly improved at week 8 compared 
with baseline (3.71 [1.14] vs 6.07 [0.59]; P < 0.002); the differences at weeks 
4 and 12 were nonsignificant. The between-group difference in mean (SE) VAS 
scores for pain on movement was significant only at week 12 (2.08 [0.60] in the 
GC group vs 4.00 [1.39] in the control group; P = 0.029) (Table II). 
Lumbar  Stiffness 
Although the mean (SE) VAS score for lumbar stiffness was significantly im- 
proved from baseline at weeks 4 and 12 in the patients treated with GC (3.57 
[0.89] at week 4 and 1.01 [0.39] at week 12 vs 5.94 [0.81] at baseline; P< 0.008 and 
P = 0.011, respectively), this improvement was not observed at any time point in 
the control group. The improvement in the GC group was significantly greater 
compared with that in the control group at week 12 (P = 0.011) (Table If). 
Quality of Life 
Oswestry Disability Questionnaire 
The mean score on the ODQ 16,18-2° was significantly improved from baseline 
at weeks 4, 8, and 12 in the GC group (all, P < 0.001) (Table If). In the control 
group, the score was not improved from baseline until week 12 (P < 0.001). At 
the end of the 12-week study, a significant difference in ODQ score between the 
2 groups was observed (P = 0.028). 
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Table II. Cl inical parameters  over  12 weeks  of admin is t ra t ion  of  g lucosamine  complex  
(GC) (n = 17) or  p lacebo (cont ro l )  (n = 15) in pat ients  w i th  chron ic  low back 
pain (N = 32). Values are mean (SE) unless o therwise  noted.  
0 Weeks 
Parameter (Baseline) 4 Weeks 8 Weeks 12 Weeks 
Score for pain at rest a 
GC 4.65 (0.69) 2.47 (0.72) b,c 1.78 (0.87) b,c 0.59 (0.33) b,d 
Control 3.47 (0.57) 3.60 (1.03) 3.75 (0.94) 2.01 (1.1 8) 
Score for pain 
on movement  a
GC 6.1 7 (0.38) 3.60 (0.73) b 2.38 (0.68) 2.08 (0.60) e 
Control 6.07 (0.59) 5.40 (1.83) 3.71 (1.14) e 4.00 (1.39) 
Score for lumbar 
stiffness a 
GC 5.94 (0.81) 3.57 (0.89)9 3.56 (1.34) 1.01 (0.39) h,i 
Control 4.13 (0.89) 2.86 (0.86) 2.00 (1.08) 2.63 (0.98) 
QOL score (ODQJ) 
GC 30.05 (1.80) 23.82 (2.56) b 22.22 (2.20) b 18.69 (1.94) b,k 
Control 25.80 (2.28) 21.00 (2.89) 23.71 (3.96) 18.00 (4.1 7) b 
QOL score (RMDQ I) 
GC 9.76 (1.09) 6.80 (1.52) b 5.67 (1.65) b 5.38 (1.20) b 
Control 7.86 (1.23) 4.75 (2.17) b 6.71 (1.49) b 4.57 (1.68) b 
Anti-inflammatory/ 
analgesic use, no. 
GC 7 2 2 2 
Control 8 6 6 6 
QOL = quality of life; ODQ = Oswestry Disability Questionnaire 16,18 20; RMDQ = Roland-Morris Disability 
Question naire. 18,19 
a 10-cm visual analog scale: 0 = none to 10 = worst possible. 
bp < 0.001 versus baseline. 
cp < 0.001 versus control group. 
dp < 0.01 versus control group. 
ep = 0.029 versus control group. 
f P < 0.002 versus baseline. 
gP < 0.008 versus baseline. 
hp = 0.011 versus control group. 
i p = 0.011 versus baseline. 
i ODQ scale 16,18 2o: 0 = no disability to 60 = maximal disability. 
kp = 0.028 versus control group. 
I RMDQ scale18,19:0 = no disability to 24 = severe disability. 
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Roland-Morris Disabifity Questionnaire 
The mean RMDQ 18,19 scores were significantly improved from baseline at 
weeks 4, 8, and 12 in both groups (all, P < 0.001) (Table II), but no significant 
between-group differences were found. 
Patient Global Assessment 
After 12 weeks of treatment, 8 of 17 patients in the GC group regarded their 
condition as well improved and were considered responders. 
Of the 7 GC-treated patients receiving anti-inflammatory/analgesic drugs before 
enrollment, 5 were able to spontaneously discontinue their anti-inflammatory/ 
analgesic drug use within the first 4 weeks, whereas of the 8 patients receiving 
anti-inflammatory/analgesic drugs before enrollment in the control group, 2 dis- 
continued use (P < 0.001). 
Responders 
In the subanalysis of patients in the GC group classified as responders (8 pa- 
tients) or nonresponders (9), the clinical parameters (age, sex, duration of symp- 
toms, pain on rest and movement, intensity of lumbar stiffness, and the ODQ and 
RMDQ scores) were statistically similar between the 2 subgroups (Table llI). 
Tolerability 
Abdominal discomfort (gastralgia) was reported at 8 weeks by i patient in the 
GC group and by 1 patient in the control group. No other adverse vents were 
reported. None of the patients discontinued treatment due to an adverse vent. 
Table III. Characteristics of responders* and nonresponders to 12 weeks of adminis- 
trat ion of glucosamine complex (GC) in patients with chronic low back pain. 
Values are mean (SE). 
Responders Nonresponders 
Characteristic (n = 8) (n = 9) P 
Age, y 71 (8) 63 (15) 0.18 
Duration of lumbar pain, y 9 (13) 8 (6) 0.81 
Score for pain at rest t 5.44 (2.55) 3.75 (3.10) 0.23 
Score for pain on movement t 6.11 (0.92) 6.25 (2.1 2) 0.87 
Score for lumbar stiffness t 6.55 (3.35) 5.25 (3.45) 0.44 
QOL score (ODQ~) 32.55 (7.90) 27.25 (6.13) 0.14 
QOL score (RMDQ§) 10.88 (4.13) 8.50 (4.84) 0.28 
QOL = quality of life; ODQ = Oswestry Disability Questionnaire 16J8 2o; RMDQ = Roland-Morris Disability 
Questionnaire.18,19 
* Responders were defined as patients who positively assessed the efficacy of the GC. 
t 10-cm visual analog scale: 0 = none to 10 = worst possible. 
$ODQ scale 16J8 2o: 0 = no disability to 60 = maximal disability. 
§RMDQ scalelSJg: 0 = no disability to 24 = severe disability. 
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DISCUSSION 
The results of this preliminary study suggest hat adding the GC to the CT reg- 
imen for chronic low back pain contr ibutes to faster and more significant 
improvements in pain at rest, pain on movement,  and lumbar stiffness (as mea- 
sured using pain and stiffness scales), and QOL (as measured using QOL ques- 
tionnaires) compared with CT alone. 
Improvement, based on the results of the ODQ, 16'18-20 was  found with GC use, 
but the GC did not add a significant additional benefit based on the results of 
the RMDQ. 18,19 The lack of a difference found with the RMDQ 18,19 might mean a 
lack of benefit, or might be the result of a statistical limitation (small number 
of patients) or a methodologic limitation (lack of sensitivity of the RMDQ for 
chronic low back pain) to objectify an additional benefit. 
The mode of action of the GC remains unclear. It contains glucosamine, natural 
sulfur, an extract of Ribes nigrum, and silicon. Although this group of compounds 
is used for the treatment of rheumatic pain, the precise role of each component 
has not been identified. 1°-15 However, a hypothesis concerning the mode of action 
of the GC can be proposed based on the results of the present study. First, the 
slowness of the improvement (4 weeks vs a few hours or days with central or 
medullary analgesic effect) 5and the fact that the lumbar anatomic structures have 
little cartilage (compared with those in the knee) 5 render a chondroprotective 
effect unlikely. A slow anti-inflammatory or analgesic mode of action is more likely 
based on the data. The benefit could be due to the individual components in the 
GC or their combination. The treatment also was found to work on different pain 
parameters and might provide clinical benefit in addition to that of CT (based on 
rehabilitation techniques with suppleness and analgesic effects). 
Based on the literature search, these data, if confirmed, are virtually the first 
to suggest hat glucosamine alone or in combination with additional components 
could be associated with an analgesic/anti-inflammatory benefit in patients with 
low back pain, a condition not included to date as a goal of the potential develop- 
ment of GC. The circumferences of the lumbar disks and the interapophyseal 
caps are innervated by delicate fibers that can become the center of a slower, 
neurogenic inflammatory process, causing the release of neurogenic mediators 
(eg, substance P, calcitonm gene-related peptide) and non-neurogenic mediators 
(eg, serotonin, histamine), and that could be a potential target of the GC. 5'21'23 
Study Limitations 
Interpretation of the present data is difficult because of the small number of 
patients, the lack of a control group, and the open-label design. 
The number of patients in this study was limited. It cannot be ruled out that 
the patients initially experienced ifferent evolved types of chronic low back 
pain and that these distinctions are difficult to resolve with this small number 
of participants. 
The GC was well tolerated with the exception of gastralgia reported in 1 pa- 
tient. However, this adverse effect might have been caused by the analgesic/ 
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anti-inflammatory treatment instead of the GC, because gastralgia lso oc- 
curred in 1 patient who was not receiving GC. In addition, the symptom did 
not necessitate interruption of the treatment. 
Because this was an open-label pilot study, methodologic bias cannot be 
ruled out, especially because the study contained subjective assessments (eg, 
quantification of pain and stiffness). Nonetheless, the study employed commonly 
used questionnaires such as the ODQ, 16'18-20 which can measure disability due 
to pain more objectively compared with patient or clinician global assessment. 
Because low back pain can improve spontaneously, a placebo effect may have 
occurred. However, the placebo effect is generally time limited, 2,5-7 whereas the 
improvement associated with the GC continued through week 12 of treatment, 
with most of the differences being statistically significant. If the present data are 
confirmed, the GC could be of potential benefit in low back pain. 
The original composition of this GC did not allow extrapolation of these 
results with regard to lumbalgia to other "chondroprotector" substances with 
glucosamine alone or its derivatives. If these findings were confirmed, this GC 
might find a place in the treatment of chronic low back pain. 
CONCLUSIONS 
In this study in patients with chronic low back pain, analgesic effect and im- 
provement in QOL were found with the use of glucosamine sulfate complex. The 
study drug was well tolerated. 
ACKNOWLEDGMENTS 
This study was sponsored by Pierre Fabre Sant6, Benelux, Brussels, Belgium. 
The authors thank C. Melot, MD, PhD, University of Brussels, Brussels, Belgium, 
for statistical analysis of the data, and Paul Kretchner, MD, PhD, San Francisco 
Edit, San Francisco, California, for his skillful help in editing the manuscript. 
REFERENCES 
1. Houpt JB, McMillan R, Wein C, Paget-Dellio SD. Effect of glucosamine hydrochloride 
in the treatment of pain of osteoarthritis of the knee. J Rheumatol. 1999;26:2423- 
2430. 
2. Lozada C, Altman R. Management oflimb joint osteoarthritis. In:Harris ED Jr, Kelley 
WN, eds. Kelley's Textbook of Rheumatology. 7th ed. Philadelphia, Pa: Elsevier 
Saunders; 2005:1856-1861. 
3. Bruyere O, Pavelka K, Rovati LC, et aL Glucosamine sulfate reduces osteoarthritis 
progression i postmenopausal women with knee osteoarthritis: Evidence from two 
3-year studies. Menopause. 2004; 11:138-144. 
4. Poolsup N, Suthisisang C, Channark P, Kittikulsuth W. Glucosamine long-term treat- 
ment and the progression of knee osteoarthritis: Systematic review of randomized 
controlled trials. Ann Pharmacother. 2005;39:1080-1087. 
520 
L. Tant et aL 
5. Borenstein D. Low back pain and lumbar spinal stenosis. In: Hochberg MC, Silman A, 
Smolen J, et al, eds. Rheumatology. 3rd ed. St. Louis, Mo: Mosby; 2003:583-613. 
6. van Tulder MW, Scholten R J, Koes BW, Deyo RA. Nonsteroidal anti-inflammatory 
drugs for low back pain: A systematic review within the framework of the Cochrane 
Collaboration Back Review Group. Spine. 2000;25:2501-2513. 
7. Sarzi-Puttini P, Cimmino MA, Scarpa R, et al. Osteoarthritis: An overview of the dis- 
ease and its treatment strategies. Semin Arthritis Rheum. 2005;35(Suppl 1):1-10. 
8. Berman B, Gournelos E, Lewith G. Complementary and alternative medicine. In: 
Hochberg MC, Silman A, Smolen J, et al, eds. Rheumatology. 3rd ed. St. Louis, Mo: 
Mosby; 2003:505-516. 
9. Anderson JW, Nicolosi R J, Borzelleca JE Glucosamine effects in humans: A review of 
effects on glucose metabolism, side effects, safety considerations and efficacy. Food 
Chem Toxicol. 2005;43:187-201. 
10. Dobson G. Leaf lipids of Robes nigrum: A plant containing 16:3, alpha-18:3, gamma- 
18:3 and 18:4 fatty acids. Biochem Soc Trans. 2000;28:583-586. 
11. Garbacki N, Angenot L, Bassleer C, et al. Effects of prodelphinidins i olated from 
Ribes nigrum on chondrocyte metabolism and COX activity. Naunyn Schmiedebergs 
Arch Pharmacol. 2002;365:434-441. 
12. Lawrence RM. Methylsulfonylmethane: A double blind study of its use in degenera- 
tive arthritis. Int J Antiaging Med. 1998;1:50. 
13. Moh JH, Choi YH, Lim KM, et al. A prodrug approach to COX-2 inhibitors with methyl- 
sulfone. Bioorg Med Chem Lett. 2004; 14:1757-1760. 
14. Parcell S. Sulfur in human nutrition and applications in medicine. Altern Med Rev. 
2002;7:22-44. 
15. Schiano A, Eisinger F, Detolle P, et al. Silicon, bone tissue and immunity [in French]. 
R e v Rhum Mal Osteoartic. 1979;46:483-486. 
16. Pocock SJ. Clinical Trials: A Practical Approach. New York, NY: Wiley; 1983. 
17. Atromal (glucosamine complex) [product information]. Toulouse, France: Laboratories 
Dolisos SA; 2005. 
18. Bradley LA. Pain measurement i  arthritis. Arthritis Care Res. 1993;6:178-186. 
19. Stratford PW, Binkley J, Solomon P, et al. Defining the minimum level of detectable 
change for the Roland-Morris questionnaire. Phys Ther. 1996;76:359-365. 
20. Fairbank JC, Couper J, Davies JB, O'Brien JP. The Oswestry low back pain disability 
questionnaire. Physiotherapy. 1980;66:271-273. 
21. Ward M. Assessment of health outcomes. In: Harris ED Jr, Kelley WN, eds. Kelley's 
Textbook ofRheumatology. 7th ed. Philadelphia, Pa: Elsevier Saunders; 2005:435--446. 
22. Winer BJ. Statistical Principles in Experimental Design. 3rd ed. New York, NY: McGraw- 
Hill; 1991. 
23. Datta D, Mirza SK, White A. Low back pain. In: Harris ED Jr, Kelley WN, eds. Kelley's 
Textbook ofRheumatology. 7th ed. Philadelphia, Pa: Elsevier Saunders; 2005:588-600. 
Address correspondence to: Laure Tant, MD, Division of Rheumatology and 
Physical Medicine, Erasme University Hospital, Brussels, Belgium. E-mail: 
ltant@ulb.ac.be 
521 
